When Cancer Strikes, Strike Back

<b>When Cancer Strikes, Strike Back</b>“></td>
<td>
<p>(<a href=NewsUSA) – Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. Last year, the American Cancer Society estimated that nearly 16,000 Americans were diagnosed with this disease.

Jason Whiting, Sr. never imagined he would be one of them.

Several years ago, 36 year-old Jason, a Baltimore-based father of two, visited his doctor to see why the lymph nodes in his neck were enlarged. He was immediately referred to Dr. Stephen Noga, director, medical oncology/hematology at Alvin & Lois Lapidus Cancer Institute, who completed blood and bone marrow tests, which confirmed that Jason had CLL. With the diagnosis came mixed emotions — fear, shock and relief that it was detected early.

Given the early-stage diagnosis, Jason experienced minimal symptoms, and he and Dr. Noga decided to initially take a “watch and wait” approach to treatment -; a common practice for CLL patients. Over the next several years, Jason had blood tests and CAT scans to monitor his disease progression.

In May 2009, Jason experienced discomfort in his chin and neck, and a CAT scan showed that the cancer had spread to lymph nodes in his abdomen and chest. Both Jason and Dr. Noga agreed -; it was now time to begin treatment and the fight against cancer.

“It was important that Jason be comfortable with his treatment approach, and we spent a lot of time discussing options,” said Dr. Noga.

Dr. Noga prescribed TREANDA, and after six cycles of TREANDA, Jason has achieved partial remission.

Jason didn’t fight this battle alone. Throughout his treatment, Jason relied on the support of his family and his coworkers.

“When I was diagnosed, I made a decision to beat CLL,” said Jason. “I knew I had to stay positive and motivated so the cancer would not get the best of me. I am thankful for everyone who supported me through the experience.”

Grateful to have achieved partial remission, Jason can be found practicing martial arts and spending time with his children — something that he never takes for granted. Individual results may vary.

TREANDA® (BENDAMUSTINE HCL) FOR INJECTION IS APPROVED BY THE FDA FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB-CONTAINING REGIMEN. TREANDA IS ALSO APPROVED FOR THE TREATEMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). EFFICACY RELATIVE TO FIRST LINE THERAPIES OTHER THAN CHLORAMBUCIL HAS NOT BEEN ESTABLISHED.

The following serious adverse reactions have been associated with TREANDA: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation. Some of these reactions have been fatal, including myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN). Patients should be monitored closely for these reactions and treated promptly if any occur. Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment. Myelosuppression is frequently severe and should be expected when treating patients with TREANDA.

TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA.

The most common non-hematologic adverse reactions associated with TREANDA (frequency 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common hematologic abnormalities associated with TREANDA (frequency 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.

FOR MORE INFORMATION VISIT WWW.TREANDA.COM.

Sponsored by Cephalon, Inc., the makers of TREANDA.

When Breast Cancer Fights Back

<b>When Breast Cancer Fights Back</b>“></td>
<td>
<p>(<a href=NewsUSA) – We’ve all heard about the fight against breast cancer — but did you know that breast cancer fights back?

Breast cancer, the second leading cause of cancer deaths in women, is found in 1.3 million women throughout the world each year. Early detection and improved treatments have decreased death rates, but the American Cancer Society predicts that 40,910 Americans will die of breast cancer in 2009.

What makes breast cancer difficult to treat? Typically, doctors treat breast cancer through surgery to remove the tumor, followed by chemotherapy and radiation. But some cancers prove difficult to remove, others come back. And some tumors stop responding to chemotherapy drugs. When this happens, the cancer is said to have developed drug resistance.

Some cancer cells become drug resistant when they develop the ability to pump out drugs from their bodies. Other chemotherapy drugs target specific proteins within the cancer cell. In response, the cancer cells produce more of that protein. Chemotherapy drugs can destroy healthy tissue, so doctors are limited in the dosages that they can administer. The cancer cells produce more proteins than the chemotherapy drugs can target, allowing the cancer cells to overwhelm the body despite chemotherapy treatments.

But breaking-edge companies are developing new drugs that can treat resistant cancers and give patients new hope. For example, Cellceutix Corporation, a cancer and anti-inflammatory drug developer, has developed a unique technology called Kevetrin that targets growth signals in tumor cells as opposed to being toxic to all cells, which is the traditional chemotherapy treatment.

In the experiments, mice were implanted with human tumor cells known to be drug resistant. Kevetrin reduced tumor volume by 68 percent and delayed tumor growth by more than 62 percent, compared to controls.

“Kevetrin continues to demonstrate consistent success in fighting drug resistant cancers, the leading cause of chemotherapy failure,” says Mr. George Evans, CEO of Cellceutix. “We are optimistic that Kevetrin will continue to progress on the developmental pathway as a treatment for these very difficult cancers, providing hope to its patients.”

For more information about the Kevetrin experiment results, visit www.cellceutix.com.

Impacting Cancer Survival With Good Nutrition

<b>Impacting Cancer Survival With Good Nutrition</b>“></td>
<td>
<p>(<a href=NewsUSA) – Good nutrition is key to maintaining a healthy body, but bodies experiencing physical stress often require increased nutrient intake. Unfortunately, people under severe physical stress, such as people receiving chemotherapy or radiation therapy for cancer, frequently struggle with eating, which makes getting adequate nutrition difficult.

It is estimated that malnutrition and weight loss are contributing factors in one out of every five cancer-related deaths. Cancer patients have difficulty maintaining weight during their treatment for a number of reasons including side effects such as nausea, vomiting, diarrhea and dry mouth.

Cancer treatments increase the body’s need for nutrients by speeding up metabolism and limiting nutrient absorption while at the same time making it difficult to swallow and changing the way food tastes. If a patient doesn’t take in enough calories, they are unable to maintain a healthy weight, which can lead to weakness and inability to fight their disease.

Typically, cancer patients need to consume about twice the protein and 10 percent more calories than a healthy person to maintain weight and nutrition during treatment cycles.

Hospitals and cancer treatment centers are taking steps to educate these patients by offering pre- through post-treatment nutrition counseling. The American Cancer Society also offers free nutrition advice for patients and caregivers through a toll-free phone service.

Health product manufacturers are doing their part to help cancer patients address their nutritional challenges, as well. For example, The Isopure Company, LLC, recently developed Isopure Plus Nutritional Drink, a clear, fruit-flavored, protein-based drink, to help cancer patients get the extra calories and protein they need to maintain proper nutrition before, during and after treatment.

Unlike most nutritional drinks, Isopure Plus Nutritional Drink isn’t thick or milky, and it goes down easy. It delivers 15 grams of rapidly absorbable, high-quality whey protein in a single 8-ounce serving and is free from fat, gluten and lactose (which may cause stomach upset in some people). It comes in two flavors, Alpine Punch and Grape Frost and is available at chain drug retailers, grocers, nutrition centers and through online outlets.

New Treatments Help Cancer Patients

<b>New Treatments Help Cancer Patients</b>“></td>
<td>
<p>(<a href=NewsUSA) – Men facing a diagnosis of prostate cancer have more treatment options than ever before, according to the American Society for Radiation Oncology.

Prostate cancer is the most common cancer in American men. The American Cancer Society reports that, in 2008, one-quarter of all cancer diagnosed in men was prostate cancer.

But dramatic advances in treatments are allowing more men to beat the disease. Nearly 99 percent of men with prostate cancer now live five years or more after diagnosis.

Since there are several options, it’s important to discuss all the treatment methods with a radiation oncologist, a physician who specializes in treating diseases with radiation therapy, and a urologist, a surgeon who specializes in the urinary tract. They’ll help you decide which treatment plan is best for you. Possibilities include surgery, external beam radiation therapy, hormone therapy, chemotherapy or prostate brachytherapy.

Sometimes, a combination of treatments proves to be the best way to fight prostate cancer. For instance, some men choose surgery followed by external beam radiation therapy, also known as radiotherapy.

External beam radiation therapy involves a series of daily treatments that accurately deliver radiation to the prostate. This method often succeeds in treating cancer. Types of external beam radiation therapy include three dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) and proton beam therapy.

Brachytherapy involves treating the cancer by inserting radioactive sources into the gland itself. Seed implants are given by inserting small metal seeds of radioactive iodine or palladium directly into the prostate while the patient is under anesthesia.

In discussing treatment plans with your cancer specialists, be sure to keep your lifestyle in mind. Remember, every man’s cancer and lifestyle are unique. Discussions with several specialists can help you decide on the most effective and suitable treatment for your lifestyle and condition.

The American Society for Radiation Oncology has a brochure to help men and their families better understand their treatment options. Visit www.rtanswers.org or call 1-800-962-7876 for a free copy.

Ways to Lower Your Risk Of Colorectal Cancer

<b>Ways to Lower Your Risk Of Colorectal Cancer</b>“></td>
<td>
<p>(<a href=NewsUSA) – Twenty-seven-year-old Queah Habern didn’t know why she was always feeling full, and after months of sickness and misdiagnoses, she had an emergency appendectomy. Two days after surgery, she got the verdict: stage III colon cancer.

“I just remember thinking that this can’t be happening, it was surreal,” says Habern.

In fact, colorectal cancer is the second-leading cause of cancer-related deaths in the U.S. It can affect anyone, men and women, at any age.

“Tragically, there is a general perception that colorectal cancer only affects Caucasian males older than 50,” says Dr. Tonya Adams, a gastroenterologist and rectal cancer survivor who was diagnosed at age 36. “If you have a family history of colorectal cancer or polyps, a history of inflammatory bowel disease, unexplained abdominal symptoms or blood in the stool, consult with a board-certified gastroenterologist for further evaluation.”

Experts recommend that people 50 and over have a colorectal cancer screening (colonoscopy) every five to 10 years. The five-year survival rate for people whose colorectal cancer is treated at any early stage is greater than 90 percent, according to the American Cancer Society.

“We know there are effective screening technologies to help detect this cancer early and save lives,” says F. Mark Gumz, president of Olympus America Inc. “I urge all U.S. companies to include routine screenings in their employee health insurance plans.” Olympus is the leading global manufacturer of endoscopes, the medical devices commonly used for colonoscopies.

While symptoms of colorectal cancer vary, they may include vomiting, rectal bleeding or weight loss. Yet as Habern knows all too well, even simple conditions such as bloating or a feeling of fullness can be signs of something more serious. Ironically, the most common symptom is no obvious symptom at all.

A disease this stealthy can affect a wider population than commonly thought, and it’s easy to see why people have misconceptions, as Habern once did.

“I ate well. Nobody in my family has ever had colon cancer. And I definitely didn’t fit the typical 50-year-old white guy profile,” she notes.

For more information, log on to www.crcawareness.com, a comprehensive Web resource created by Olympus.

New Treatments Help Men Fight Prostate Cancer

<b>New Treatments Help Men Fight Prostate Cancer</b>“></td>
<td>
<p>(<a href=NewsUSA) – Prostate cancer is the most common form of cancer among American men. In fact, according to the American Cancer Society, as many as 1.8 million American men have the disease at any given time.

Although treatments for prostate cancer have existed for years, men can now choose from a wider variety of therapies than ever before. One in six men will develop prostate cancer at some point in his lifetime, but only one in 34 will die of the disease, and this statistic is improving with each passing year.

After being diagnosed with prostate cancer, patients will often discuss treatment methods with a radiation oncologist, a cancer doctor who specializes in treating diseases with radiation therapy, and a urologist, a surgeon who specializes in the urinary tract. Possible options for dealing with prostate cancer include surgery, external beam radiation therapy, hormone therapy, chemotherapy or prostate brachytherapy.

Sometimes, a combination of treatments proves to be the best way to fight prostate cancer; for example, some men undergo surgery followed by external beam radiation therapy, also known as radiotherapy. External beam radiation therapy, which involves a series of daily treatments to accurately deliver radiation to the prostate, often proves to be successful in treating cancer.

Brachytherapy involves treating the cancer by inserting radioactive sources into the gland itself. Seed implants are given by inserting small metal seeds of radioactive iodine or palladium directly into the prostate while the patient is under anesthesia.

To better understand your options, it’s important to speak with several cancer specialists before undergoing any kind of therapy, as each man’s cancer and health parameters are unique. Doing so can help you choose the most effective and suitable treatment for your life and condition. Organizations such as the American Society for Therapeutic Radiology and Oncology can help you learn about your treatment options and establish contact with specialists suited to your condition.

Visit www.rtanswers.org for more information.